Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia (Q34820339)

4 August 2017

1 reference

title

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia (English)

1 reference

4 August 2017

1 reference

1

Gillian M Keating

1 reference

4 August 2017

Douglas Ormrod

2

1 reference

4 August 2017

language of work or name

1 reference

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

62

1 reference

4 August 2017

1909-1944

1 reference

4 August 2017

13

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262130-00013

4 August 2017

0 references

cites work

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200262130-00013

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200262130-00013

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200262130-00013

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities

1 reference

12 December 2020

Rhabdomyolysis and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

PPARS, metabolic disease and atherosclerosis

1 reference

12 December 2020

Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms

1 reference

12 December 2020

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

1 reference

12 December 2020

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy

1 reference

12 December 2020

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

12 December 2020

Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia

1 reference

12 December 2020

Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor

1 reference

12 December 2020

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

12 December 2020

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients

1 reference

12 December 2020

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

12 December 2020

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Circulating markers of inflammation for vascular risk prediction: are they ready for prime time

1 reference

12 December 2020

Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study

1 reference

12 December 2020

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

1 reference

12 December 2020

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

New and classical risk factors--the Münster heart study (PROCAM).

1 reference

12 December 2020

Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood

1 reference

12 December 2020

Diabetic dyslipidaemia. Australian Diabetes Society position statement

1 reference

12 December 2020

AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.

1 reference

12 December 2020

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Effect of fenofibrates in heart transplant patients

1 reference

12 December 2020

Lipid-lowering drugs and homocysteine

1 reference

12 December 2020

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

12 December 2020

Identification of individuals at high risk for myocardial infarction

1 reference

12 December 2020

Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess

1 reference

12 December 2020

Uric acid: a risk factor for coronary heart disease?

1 reference

12 December 2020

Micronized fenofibrate: a new fibric acid hypolipidemic agent

1 reference

12 December 2020

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

1 reference

12 December 2020

Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.

1 reference

12 December 2020

The fibrates in clinical practice: focus on micronised fenofibrate

1 reference

12 December 2020

A new formulation of fenofibrate: suprabioavailable tablets

1 reference

12 December 2020

Fenofibrate-Induced elevation in serum creatinine

1 reference

12 December 2020

Choosing the right lipid-regulating agent. A guide to selection

1 reference

12 December 2020

Effects of fenofibrate and gemfibrozil on plasma homocysteine

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia

1 reference

12 December 2020

Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

1 reference

12 December 2020

Frequency of hypercholesterolemia after cardiac transplantation

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

1 reference

12 December 2020

The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.

1 reference

12 December 2020

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

1 reference

12 December 2020

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

12 December 2020

Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation

1 reference

12 December 2020

Systematic review on the risk and benefit of different cholesterol-lowering interventions

1 reference

12 December 2020

Homocysteine and vascular disease

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene

1 reference

12 December 2020

Diabetic dyslipidaemia: treatment implications

1 reference

12 December 2020

A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men.

1 reference

12 December 2020

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse

1 reference

12 December 2020

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

1 reference

12 December 2020

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Acute coronary syndromes: biology

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Homocysteine and cardiovascular disease

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

1 reference

12 December 2020

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

1 reference

12 December 2020

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

1 reference

12 December 2020

Fibrinogen in ischaemic heart disease

1 reference

12 December 2020

Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia

1 reference

12 December 2020

Fenofibrate improves microcirculation in patients with hyperlipidemia

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism

1 reference

12 December 2020

Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia

1 reference

12 December 2020

Direct proinflammatory effect of C-reactive protein on human endothelial cells

1 reference

12 December 2020

Micronised fenofibrate

1 reference

12 December 2020

Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial

1 reference

12 December 2020

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects

1 reference

12 December 2020

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.

1 reference

12 December 2020

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

12 December 2020

Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease

1 reference

12 December 2020

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

1 reference

12 December 2020

Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate

1 reference

12 December 2020

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

1 reference

12 December 2020

Lipids and atherogenesis in diabetes mellitus

1 reference

12 December 2020

Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias

1 reference

12 December 2020

Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.

1 reference

12 December 2020

Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

1 reference

12 December 2020

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action

1 reference

12 December 2020

New approaches to the prevention of atherosclerosis

1 reference

12 December 2020

Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

12 December 2020

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

1 reference

12 December 2020

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

12 December 2020

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

1 reference

12 December 2020

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

1 reference

12 December 2020

The Münster Heart Study (PROCAM). Results of follow-up at 8 years.

1 reference

12 December 2020

Peroxisome proliferator-activated receptors, orphans with ligands and functions

1 reference

12 December 2020

Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

1 reference

12 December 2020

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia

1 reference

12 December 2020

Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias

1 reference

12 December 2020

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

1 reference

12 December 2020

Implication of fibrate therapy for homocysteine

1 reference

12 December 2020

10.2165/00003495-200262130-00013

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1015455302

0 references

Fatcat ID

release_dzsngh6byzgktgyzkopz2rpzse

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dzsngh6byzgktgyzkopz2rpzse

24 November 2022

mapped directly with Wikidata item

1 reference